enGene (ENGN) Competitors

Aligos Therapeutics (NASDAQ:ALGS) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Does the MarketBeat Community prefer ALGS or ENGN?

Aligos Therapeutics received 16 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 64.10% of users gave Aligos Therapeutics an outperform vote.

Company	Underperform	Outperform
Aligos Therapeutics	Outperform Votes 25 64.10%	Underperform Votes 14 35.90%
enGene	Outperform Votes 9 100.00%	Underperform Votes No Votes

Which has higher valuation and earnings, ALGS or ENGN?

Aligos Therapeutics has higher revenue and earnings than enGene. Aligos Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$7.97M	89.61	-$87.68M	-$1.28	-7.14
enGene	N/A	N/A	-$99.92M	-$1.66	-4.34

Do institutionals & insiders have more ownership in ALGS or ENGN?

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 16.5% of Aligos Therapeutics shares are held by company insiders. Comparatively, 13.7% of enGene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is ALGS or ENGN more profitable?

enGene has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,100.48%. enGene's return on equity of -66.38% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,100.48%	-110.59%	-63.90%
enGene	N/A	-66.38%	-56.00%

Do analysts prefer ALGS or ENGN?

Aligos Therapeutics currently has a consensus price target of $75.00, indicating a potential upside of 720.57%. enGene has a consensus price target of $33.67, indicating a potential upside of 366.94%. Given Aligos Therapeutics' higher probable upside, equities analysts plainly believe Aligos Therapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
enGene	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, ALGS or ENGN?

Aligos Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.67, meaning that its share price is 167% less volatile than the S&P 500.

Does the media refer more to ALGS or ENGN?

In the previous week, enGene had 18 more articles in the media than Aligos Therapeutics. MarketBeat recorded 31 mentions for enGene and 13 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.31 beat enGene's score of -0.13 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	0 Very Positive mention(s)	6 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Aligos Therapeutics and enGene tied by winning 8 of the 16 factors compared between the two stocks.